Nasdaq icpt.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination ...
Company profile page for Intercept Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact informationIntercept Pharmaceuticals, Inc. (Nasdaq – ICPT) Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of ...Nov 8, 2023 · Market Capitalization. $794.77 million. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $23.18. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media Sustainability. Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Dec 23, 2022 · MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
How much institutional selling is happening at Intercept Pharmaceuticals? Institutional investors have sold a total of 20,152,041 shares in the last 24 months. This volume of shares sold represents approximately $299.76M in transactions. This page (NASDAQ:ICPT) was last updated on 11/26/2023 by MarketBeat.com Staff.
Shares of Intercept Pharmaceuticals ( ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private Italian ...MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
As of now, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) is the only company to provide positive data from its drug OCA (Obeticholic acid), after which its stocks have tripled in value.WebNEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel ...ICPT Price Action: Shares of Intercept Pharmaceuticals Services rose 6.3% to close at $9.75 on Thursday. ViewRay, Inc. (NASDAQ:VRAY) ViewRay reported worse-than-expected quarterly revenue results ...May 25, 2023 — 10:32 am EDT. The biotech sector has been in focus in the past week with key pipeline and regulatory updates. Among these, Intercept Pharmaceuticals ICPT was down significantly ...Jan 19, 2023 · The FDA has accepted Intercept’s latest application for the drug in patients with NASH-related pre-cirrhotic liver fibrosis, the company said Thursday. The FDA has set a target decision date of ...
18.89%. $10.02M. Gilead Sciences Inc. 0.36%. $97.68B. ICPT | Complete Intercept Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial ...
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) develops novel synthetic therapeutics for chronic liver diseases. The company raised $75 million after selling 5 million shares at $15 per share during its IPO. Intercept’s key product is a bile acid, intended to cure a chronic liver disease called biliary primary cirrhosis (PBC). The company ...Web
28 thg 9, 2023 ... ... stock market regulator / authority. I discuss about potential trends ... #forecast and how to do icpt stock prediction ICPT STOCK ANALYSIS ...NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...Intercept Pharmaceuticals Inc stock price (ICPT) NASDAQ: ICPT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Intercept Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the developmen...Under the terms of the merger agreement, Alfasigma has agreed to commence a cash tender offer to acquire all issued and outstanding shares of Intercept common stock for US$19.00 per share in cash ...NASDAQ: ICPT Intercept Pharmaceuticals. Intercept shares more than quadruple following positive clinical data for its chronic liver disease drug. Is now the time to sell or can shares head even ...WebNASDAQ: ICPT Intercept Pharmaceuticals. News that a warning letter related to the company's drug Ocaliva was recently sent out to the healthcare community causes traders to head for the exits.
ICPT Stock 12 Months Forecast. $19.00. (0.00% Upside) Based on 9 Wall Street analysts offering 12 month price targets for Intercept Pharma in the last 3 months. The average price target is $19.00 with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 0.00% change from the last price of $19.00. NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...NASDAQ:ICPT opened at $19.00 on Wednesday. The company has a quick ratio of 2.52, a current ratio of 4.22 and a debt-to-equity ratio of 3.12. Intercept Pharmaceuticals has a 1-year low of $8.82 and a 1-year high of $21.86. The firm has a market capitalization of $794.77 million, a price-to-earnings ratio of -12.84 and a beta of 0.88.... ICPT(ICPT)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与ICPT(ICPT) ... ICPT NASDAQ:ICPT Intercept Pharmaceut. 添加自选 在APP中查看.BOLOGNA, Italy, November 08, 2023--Alfasigma S.p.A. ("Alfasigma") announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. ("Interstellar"), successfully ...FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's (NASDAQ: ICPT) Ocaliva 25 mg, also known as Obeticholic ...WebNEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...
Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Nov 28, 2023 · Bank of New York Mellon Corp lifted its stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Free Report) by 24.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 218,165 shares of the biopharmaceutical company’s stock after purchasing an additional 42,384 shares during […]
Morristown, New Jersey, UNITED STATES. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development ...Sep 26, 2023 · Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT) Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of ... FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's (NASDAQ: ICPT) Ocaliva 25 mg, also known as Obeticholic ...WebNEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...14 thg 11, 2023 ... Intercept Pharmaceuticals (NASDAQ:ICPT – Get Free Report) and Regen BioPharma (OTCMKTS:RGBP – Get Free Report) are both medical companies, ...MORRISTOWN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...... (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NXGN). GlobeNewswire Sep ...
For Intercept Pharmaceuticals Inc (NASDAQ:ICPT), B. Riley Securities upgraded the previous rating of Neutral to Buy. In the third quarter, Intercept Pharmaceuticals showed an EPS of $0.63 ...Web
(Nasdaq: ICPT) today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting to ...
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...Nasdaq ICPT (Intercept Pharmaceuticals) is a renowned biopharmaceutical company that has been making significant strides in the field of liver disease treatment. With a focus on developing innovative therapies, ICPT aims to address the unmet medical needs of patients suffering from various liver conditions.MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Contact Data Contact For more information about Intercept Pharmaceuticals, please contact: Mark Vignola +1-646-747-1000 [email protected] Christopher Frates +1-646-757-2371 media ...Intercept's Financials. Intercept's Q1 2023 financial results showed $68.0 million in net sales, a rise from $59.2 million in Q1 2022. Operating expenses were $99.6 million, with $93.6 million as ...Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT) Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of ...Intercept Pharma(NASDAQ: ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. The company’s drug Ocaliva has been approved for primary ...... (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NXGN). GlobeNewswire Sep ...MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Nasdaq ICPT (Intercept Pharmaceuticals) is a renowned biopharmaceutical company that has been making significant strides in the field of liver disease treatment. With a focus on developing innovative therapies, ICPT aims to address the unmet medical needs of patients suffering from various liver conditions.
Jun 3, 2022 · MORRISTOWN, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Market traders watched Intercept's recent clinical trial with anticipation. Unfortunately, the results fell short and ICPT stock is tanking. ICPT stock investors are concerned about disappointing clinical trial results Source: Postmodern St...Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. Intercept Pharmaceuticals, Inc. Common Stock (ICPT) …Instagram:https://instagram. honda motor stockbest medicaid plan nycdakota gold corpbarrons baseball We recognized $100.4 million in non-GAAP adjusted net sales and $71.8 million in U.S. net sales in the second quarter 2022 as compared to non-GAAP adjusted net sales of $96.6 million and $68.2 ... graphene stock pricechase options trading MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Nasdaq 14,155.89 +61.51(+0.44%) Russell 2000 1,813.27 +14.95(+0.83%) Crude Oil 77.14 -1.12(-1.43%) Gold 1,961.80 -4.70(-0.24%) Advertisement Intercept Pharmaceuticals, Inc. … what is es futures 3 thg 11, 2023 ... (ICPT). Category: Industry Announcement. Markets Impacted: The Nasdaq Stock Market ...NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...Jan 19, 2023 · The FDA has accepted Intercept’s latest application for the drug in patients with NASH-related pre-cirrhotic liver fibrosis, the company said Thursday. The FDA has set a target decision date of ...